Regenetech grants local cellXpansion license to Regenevita

USA-based Regenetech has signed a Mexican, country-exclusive license for its cellXpansion technology with local company Regenevita. The exclusive agreement will allow Regenetech's cellXpansion technology to be made available for clinical applications in the country.

Under the terms of the exclusive deal, Regenetiva will use the technology to expand human progenitor cells from blood for use in R&D activities with the ultimate objective of commercializing the stem cell expansion process for the benefit of patients in Mexico. Financial terms of the agreement were not disclosed.

Carlos Morett, chief executive of Regenevita, said: "we are delighted to begin working with Regenetech and their strong cellXpansion technology position in this area. We believe we can enable the widespread use in Mexico of tissue regeneration therapy, revolutionary medical treatment that benefits all people, with cellXpansion technology." David Bonner, CEO of Regenetech, added: "we are optimistic that this agreement will lead to increased, rapid innovations in the regenerative therapy field, expedite human clinical studies, and ultimately, lead to clinical use."